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We tested the hypothesis that levels of pentraxin high sensitiv-
ity C-reactive protein and pentraxin 3 might be correlated with
cardiovascular complications in patients with essential throm-
bocythemia and polycythemia vera. High sensitivity C-reactive
protein and pentraxin 3 were measured in 244 consecutive
essential thrombocythemia and polycythemia vera patients in
whom, after a median follow up of 5.3 years (range 0-24), 68
cardiovascular events were diagnosed. The highest C-reactive
protein tertile was compared with the lowest (>3 vs. <1 mg/L)
and correlated with age (P=0.001), phenotype (polycythemia
vera vs. essential thrombocythemia, P=0.006), cardiovascular
risk factors (P=0.012) and JAK2V617F allele burden greater than
50% (P=0.003). Major thrombosis rate was higher in the high-
est C-reactive protein tertile (P=0.01) and lower at the highest
pentraxin 3 levels (P=0.045). These associations remained sig-
nificant in multivariate analyses and indicate that blood levels
of high sensitivity C-reactive protein and petraxin 3 independ-
ently and in opposite ways modulate the intrinsic risk of car-
diovascular events in patients with myeloproliferative disor-
ders.
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ABSTRACT
Introduction 
Management of polycythemia vera (PV) and essential throm-
bocythemia (ET) poses a significant challenge, and a risk-ori-
ented therapeutic approach is recommended in order to avoid
inappropriate exposure to potentially leukemogenic cytotoxic
drugs on one side or suboptimal treatment on the other.
Established risk factors for cardiovascular events are represent-
ed by older age and previous thrombosis. Low-risk subjects are
younger (< 60 years) and asymptomatic patients, while older
subjects and those with a history of thrombosis are categorized
at high risk  for major vascular events. There is now consider-
able interest in moving  beyond these established risk factors,
especially in the young or asymptomatic low- and intermedi-
ate-risk individuals not without risk of thrombosis.1,2 Factors
that might improve the vascular risk assessment in myelopro-
liferative neoplasms are now being examined in large observa-
tional studies with adequate follow up for vascular events.
From these analyses, novel risk predictors have been recog-
nized and, as in the general population,3 white blood cell count
is emerging as a new marker to predict future events.4-6 It is
important to note the observations that leukocytosis and
leukocyte activation are sustained by JAK2V617F gene expres-
sion profile of neutrophils found to be similar to G-CSF activat-
ed granulocytes.7
Two other inflammatory biomarkers, belonging to the
superfamily of pentraxins have been found to play a role as
markers of thrombosis and atherogenesis in the general pop-
ulation. The first is the short pentraxin C-reactive protein,
mainly produced in hepatocytes, following stimulation by
cytokines, especially interleukin-6 (IL-6). The introduction of
high sensitivity assays has allowed routine measurement
and, based on epidemiological studies, high-sensitivity C-
reactive protein (hs-CRP) has been incorporated into risk
assessment for cardiovascular disease.8 The second is the
long pentraxin-3 (PTX3), an acute-phase reactant consid-
ered more closely related to cardiac injuries such as
myocardial infarction than C-reactive protein.9,10
However, whether PTX3 plays a role in the pathogenesis
of thrombosis is still unclear. PTX3 is mainly produced by
dendritic cells, macrophages, activated leukocytes and
endothelial cells, and not by the liver, in response to pri-
mary inflammatory stimuli such as interleukin-1, tumor
necrosis factor but not IL-6.11
We tested the hypothesis that blood levels of hs-CRP and
PTX3 can be correlated with thrombotic complications in
patients with essential thrombocythemia and poly-




Permission was obtained from the Institutional Review Boards
to review the medical records. Blood samples of 244 patients with
essential thrombocythemia and polycythemia vera, diagnosed
according to WHO 2008 criteria, were obtained from consecutive,
well characterized patients, regularly followed-up in two Italian
hematological centres (Bergamo and Florence). Blood samples
were obtained at the last follow-up visit (median time from diag-
nosis 5.3 years, range 0-24 years). Cardiovascular risk factors at
presentation were smoking, diabetes and hypertension. Sixty-
eight major thrombotic events (myocardial infarction, stroke,
peripheral arterial thrombosis and venous thromboembolism)
were objectively documented as previously reported.5 JAK2V617F
mutation was carried out according to the already published
assay12 and classified as having low allele burden (<50%, heterozy-
gous) or high allele burden (≥50%, homozygous).
Technical information
High sensitivity C-reactive protein 
Hs-CRP was measured by a latex immunoassay (CardioPhase
High Sensitivity C-Reactive Protein Siemens Healthcare
Diagnostic Inc, Italy) based on anti-CRP antibody absorbed to
latex particles. Agglutination resulting from interaction with C-
reactive protein in plasma samples was read at 571 nm by means
of an automatic analyzer. Normal values in 32 healthy controls
ranged from 0.1 to 2.86 mg/L (median 0.57 mg/L).
PTX3
PTX3 plasma levels were measured by an in-house Sandwich
ELISA as previously described.9 Detection limit is 100 pg/ml and
inter-assay variability is 8-10%. Briefly, ELISA plates (96 well;
Nunc Immuno Plate, MaxiSorp; Nunc) were coated with 100
ng/well of rat monoclonal anti-PTX3 antibody (MNB4) diluted in
coating buffer (15 mM carbonate, Na2CO3 + NaHCO3, buffer pH
9.6) by overnight incubation at 4°C. Washing buffer (Dulbecco’s
phosphate buffered saline (PBS) containing 0.05% Tween 20) was
used to wash plates thoroughly after each passage. Non-specific
binding to the plates was blocked with 5% dry milk in phosphate
buffered saline for 2 h at room temperature before adding recom-
binant human PTX3 standards (100 pg/ml to 2 ng/mL) or unknown
samples. After incubation for 2 h at 37°C, 25ng/well of biotin con-
jugated anti-PTX3 rabbit IgG were then added (1 h at 37°C) fol-
lowed by the addition of 100 μL of streptavidin-peroxidase
(BioSpa, Milan, Italy). Finally, 100 μL of ABTS chromogen (Pierce)
were added and absorbance values were read at 450 nm in an auto-
matic ELISA reader. Normal values in 32 healthy controls ranged
from 0.45 to 2.9 ng/mL (median 1.74 ng/mL).
Statistics
Rounded tertiles of hs-CRP and PTX3 distribution were used as
cut-offs for all the analyses. Univariate analysis compared patients
in the first tertile with patients in the third tertile, using c2 test (or
Fisher’s exact test for cell frequencies less than 5) for categorical
variables (sex, polycythemia vera or essential thrombocythemia,
cardiovascular risk factors, JAK2V617F status and allele burden,
treatments and thrombosis occurring at presentation or during fol-
low up) and non-parametric K-sample test for equality of medians
was used to analyze age. ANCOVA analysis was performed to test
the difference in hs-CRP and PTX3 distributions between cate-
gories corrected by age as a covariate.
Multivariate models considered sex (male vs. female), age at
sampling (≥ 60 years vs. < 60 years), disease at diagnosis (essential
thrombocythemia vs. polycythemia vera), presence of almost one
cardiovascular risk factor (yes vs. no), JAK2V617F allele burden
(<50%, ≥50% vs. JAK2 wild type) and hystory of hydroxyurea
treatment (yes vs. no). Logistic unadjusted and sequentially adjust-
ed multivariate models were performed to assess for effect modi-
fication.
Results and discussion
Patients’ characteristics at presentation are shown in
Table 1 and clearly reflect the variety of clinical features
found in routine clinical practice of care of unselected essen-
tial thrombocythemia and polycythemia vera patients. As
expected, there was a prevalence of females in essential
thrombocythemia and a slight preponderance of males in
polycythemia vera. JAK2V617F mutation was present in
97% (n=69) and in 63% (n=108) of polycythemia vera and
essential thrombocythemia, respectively. Sixty-eight major
thrombotic events were registered before blood sampling.
Thirty-eight episodes (56%)  were documented  at diagno-
sis and 30 (44%) during follow up. Aspirin was prescribed
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Table 1. Characteristics of patients participating in the study.
                                                                    ET                           PV
N                                                                                173                                71
Age (years, median, range)                          61 (21-96)                  66 (34-94)
Sex M/F (%)                                                  62/111 (36/64)            43/28 (61/39)
Cardiovascular risk factors* (%)                 39 (22.5)                     26 (37%)
JAK2V617F/ JAK2 wt                                     108/64 (63/37)              69/2 (97/3)
If JAK2mutated,  <50% / >50%                  101/6 (94/6)              47/22 (68/32)
Thrombosis any time, n (%)                           44 (25)                        24 (31)
AMI                                                                    14 (32)                         5 (21)
Stroke - TIA                                                     16 (36)                         7 (29)
PAT                                                                      0 (0)                            1 (4)
VTE                                                                    14 (32)                        11 (46)
Follow up** (years, median, range)     5.36 (0.25-24.5)         5.05 (0.41-22.2)
Any treatment, Yes/No (%)                       153/20 (88/12)              66/5 (93/7)
If yes,                                        Aspirin         139 (80)                       41 (58)
Phlebotomy                  -                              36 (51)
Myelosuppressive drugs           101 (59)                       46 (65)
AMI: acute myocardial infarction; TIA: cerebral transient ischemic attack; PAT: peripheral
arterial thrombosis; VTE: venous thromboembolism. *Defined as presence of smoking
and/or diabetes and/or hypertension **Time elapsed from diagnosis to blood sample
(last follow up).
Table 2. Meaningful variables associated with values of hs-CRP and PTX3.
hs-CRP* PTX3*
<1 1 - 3 > 3 P† < 2.5 2.5 - 4.5 > 4.5 P‡
N=244 73 93 78 75 84 85
Age, years (median, range) 56 (21-89) 61 (33-89) 73 (30-96) <0.0001 62 (21-87) 62 (30-96) 66 (24-94) 0.43
Sex M/F (%) 28/45 (38/62) 39/54 (42/58) 38/40 (49/51) 0.20 34/41 (45/55) 37/47 (44/56) 34/51 (40/60) 0.50
ET/PV (%) 59/14 (81/19) 67/26 (72/28) 47/31 (60/40) 0.006 46/29 (61/39) 68/16 (81/19) 59/26 (69/31) 0.28
CV risk factors yes/no, n (%) 10/63 (14/86) 31/62 (33/67) 24/54 (31/69) 0.012 27/48 (36/64) 23/61 (27/73) 15/70 (18/82) 0.0085
JAK2V617F / JAK2 wild type, n (%) 52/21 (71/29) 69/23 (75/25) 56/22 (72/28) 0.94 56/19 (75/25) 58/25 (70/30) 63/22 (74/26) 0.94
If JAK2mutated,            <50% / >50% 48/4 (92/8) 62/7 (90/10) 38/17 (69/31) 0.003 51/5 (91/9) 52/6 (90/10) 45/17 (73/27) 0.01
Any treatment, yes/no (%) 65/8 (89/11) 82/11 (88/12) 72/6 (92/8) 0.49 64/11 (85/15) 77/7 (92/8) 78/7 (92/8) 0.20
If yes,         Aspirin 58 (79) 66 (71) 56 (72) 0.27 47 (63) 70 (83) 63 (74) 0.12
Phlebotomy 8 (11) 12 (12) 16 (21) 0.15 12 (16) 10 (12) 14 (16) 0.96
Myelosuppressive drugs 38 (52) 53 (57) 56 (72) 0.01 46 (61) 48 (57) 53 (62) 0.89
Thrombosis 13 (17) 27 (28) 28 (36) 0.01 29 (39) 18 (21) 21 (25) 0.045
* Rounded tertiles used as cut-offs. †Tests comparing values of h-CRP >3 mg/L in ET and PV patients with those who had values <1 mg/L of the same distribution. ‡Tests comparing values
of PTX3 > 4.5 ng/mL in ET and PV patients with those who had values < 2.5 ng/mL of the same distribution.
in the large majority of cases and chemotherapy (hydrox-
yurea) was given in 59% and 65% of essential thrombo-
cythemia and polycythemia vera cases, respectively. 
Clinical and hematological variables associated with ter-
tiles of hs-CRP and PTX3 concentrations are presented in
Table 2. 
The comparison between the third versus the first hs-CRP
tertile (hs-CRP >3 vs. <1 mg/L) showed a significant corre-
lation with age (P=0.001), with phenotype (PV vs. ET)
(P=0.006), with presence of at least one cardiovascular risk
factor (P=0.012) and with JAK2V617F allele burden greater
than 50% (P=0.003). There was a significantly higher pro-
portion of patients who needed chemotherapy when hs-
CRP values were higher than 3 mg/L. The number of
patients with major thrombosis progressively increased
according to increments of hs-CRP values (P=0.01). 
PTX3 values (<2.5; 2.5-4.5 and >4.5 ng/mL) showed a sig-
nificant correlation with JAK2V617F allele burden greater
than 50% (P=0.01) and in contrast to hs-CRP, thrombotic
episodes and cardiovascular risk factors were less frequent
in the third tertile than in the first (P=0.0085).
Online Supplementary Figure S1 provides box-plot analysis
of hs-CRP and PTX3 values in patients with and without
thrombosis both in essential thrombocythemia and poly-
cythemia vera groups. A trend towards higher hs-CRP and
lower PTX3 values in patients with thrombosis can be
observed, despite a large overlap of values (P=0.021 and P=
0.049, respectively). A comparison of patients treated versus
those not treated with hydroxyurea corrected by age
showed no difference in the distribution of these inflamma-
tory proteins (ANCOVA analysis; data not shown).
Factors influencing thrombotic risk according to hs-CRP
and PTX3  levels were tested in multivariate models (Table
3). For hs-CRP, a significant association with thrombosis
was seen when the level exceeded 3.0 mg/L. Effect sizes for
the intermediate tertile of hs-CRP (1 to 3 mg/L) were not
significant (P values ranged from 0.06 to 0.23). In multivari-
ate analysis sequentially adjusted for sex, age and essential
thrombocythemia or polycythemia vera, cardiovascular risk
factors, JAK2 mutation and hydroxyurea treatment, the
odds ratios remained significantly higher in patients with
hs-CRP levels greater than 3 mg/L. 
For PTX3, in unadjusted and progressively adjusted mod-
els, we found significant and independent association with
thrombosis, but in contrast to hs-CRP, odds ratios (OR) esti-
mates were significantly inferior to 1, indicating that the
higher the levels the less frequent were the vascular events. 
We tested the interaction between hs-CRP and PTX3 in
relation to the number of  thrombotic events in a multivari-
ate model (Online Supplementary Table S1). Patients with low
hs-CRP (< 3 mg/L) and high PTX3 (≥ 4.5 ng/mL) levels were
chosen for the reference category (n=51, OR=1). The inter-
mediate categories in which we sequentially added low
PTX3 or high hs-CRP doubled this risk (OR=1.82, P=0.18
and OR=2.13, P=0.18, respectively). The most potent and
significant correlation with thrombosis was registered in
the category with high hs-CRP and low PTX3 values
(OR=2.66, P=0.045). 
To our knowledge, this is the first study examining hs-
CRP and PTX3 blood values and their association with vas-
cular events in essential thrombocythemia and poly-
cythemia vera. 
In the general population, hs-CRP blood levels below 1,
from 1 to 3, and above 3 mg/L denote lower, average, and
higher relative risk for future vascular events.  In our essen-
tial thrombocythemia and polycythemia vera series, most
patients (n=170, 70%) had hs-CRP values much greater
than normal concentrations (> 1mg/L). 
Likewise, PTX3 plasma levels were significantly higher
than the median level of our healthy controls and normal
population.13 There have still been no large population stud-
ies to determine the epidemiological association of plasma
PTX3 and thrombosis.
In this paper, we have found that levels of these biomark-
ers in essential thrombocythemia and polycythemia vera
patients were significantly associated with the number of
major thrombotic events but the effects of this association
were completely different for hs-CRP and PTX3. For hs-
CRP, odds ratios were between 2.61 and 2.27 in all cate-
gories, indicating that the highest levels doubled the risk of
thrombosis. This novel finding in myeloproliferative neo-
plasms is consistent with results of several prospective stud-
ies showing that hs-CRP levels in the general population are
strongly associated with myocardial infarction, stroke and
venous thrombosis14 so that this inflammatory marker is
currently recommended to recognize individuals at high
cardiovascular risk and to quantify the efficacy of interven-
tions.15 For PTX3, we found that the higher the levels, the
Pentraxins in PV and ET
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fewer the patients with cardiovascular risk factors and
thrombotic events. The explanation for this hitherto
unknown effect in humans may be offered by recent exper-
imental observations showing that, in mouse models, PTX3
released from activated leukocytes has anti-thrombotic
effects, likely through a regulatory role of inflammation.16
This protective action consists in an attenuation of neu-
trophil recruitment at sites of inflammation17 through a
PTX3 binding to P-selectin on activated endothelial cells
and platelets.18,19
Blood values of hs-CRP and PTX3 were correlated with
JAK2V617F allele burden (P=0.003) suggesting that this pro-
duction may be due to the effect of gene transcription in the
case of the PTX3 gene which is transcribed by dendritic
cells, macrophages, activated leukocytes and endothelial
cells,  and may be the consequence of high levels of circu-
lating  inflammatory cytokines,  such as IL-6, in the case of
C-reactive protein.11 These experimental observations
prompted us to examine the interaction between these two
pentraxins and thrombotic events. The most frequent asso-
ciation with vascular events was detected when the lowest
PTX3 tertile interacted with the highest C-reactive protein
values. This would indicate that high PTX3 level antago-
nizes the C-reactive protein thrombotic association likely
through a reduction of vascular inflammation. Even though
our study has some limitations, such as the retrospective
design and the limited number of thrombotic events, never-
theless, it offers further evidence that thrombosis in myelo-
proliferative neoplasms are associated with a constitutive
inflammatory component.
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Table 3. Unadjusted and sequentially multivariable adjusted risk of thrombosis associated to different hs-CRP and PTX3 levels.
1.0 to 3.0 mg/L More than 3.0 mg/L 2.5 to 4.5 ng/mL More than 4.5 ng/mL
hs-CRP hs-CRP PTX3 PTX3
OR* 95% CI P OR* 95% CI P OR* 95% CI P OR* 95% CI P
Unadjusted 1.89 0.89-3.99 0.10 2.59 1.21-5.51 0.014 0.43 0.22-0.87 0.019 0.52 0.26-1.00 0.049
Adjusted for+ age1.82 0.86-3.86 0.12 2.27 1.04-4.95 0.039 0.42 0.21-0.85 0.016 0.51 0.26-1.00 0.050
+ sex 1.83 0.86-3.91 0.12 2.36 1.08-5.18 0.032 0.41 0.20-0.84 0.015 0.49 0.25-0.98 0.043
+ disease 1.80 0.84-3.85 0.13 2.25 1.02-4.96 0.045 0.44 0.21-0.90 0.025 0.50 0.25-1.00 0.050
+ CV risk factors 2.11 0.97-4.59 0.06 2.61 1.17-5.83 0.020 0.41 0.20-0.85 0.017 0.42 0.21-0.87 0.018
+ JAK2V617F 1.85 0.84-4.09 0.13 2.47 1.07-5.69 0.034 0.43 0.20-0.92 0.033 0.33 0.14-0.76 0.009
+ hydroxyurea 2.16 0.91-5.10 0.08 2.92 1.18-7.27 0.021 0.41 0.18-0.93 0.030 0.39 0.18-0.83 0.015
treatment
*Reference categories: hs-CRP < 1.0 mg/L; PTX3 < 2.5 ng/m.
References
1. Carobbio A, Finazzi G, Antonioli E,
Guglielmelli P, Vannucchi AM, Delaini F, et
al. Thrombocytosis and leukocytosis inter-
action in vascular complications of essential
thrombocythemia. Blood. 2008;112(8):
3135-7.
2. Marchioli R, Finazzi G, Landolfi R, Kutti J,
Gisslinger H, Patrono C, et al. Vascular and
neoplastic risk in a large cohort of patients
with polycythemia vera. J Clin Oncol.
2005;23(10):2224-32.
3. Mukamal KJ, Wellenius GA, Mittleman
MA. Hematologic parameters, atheroscle-
rotic progression, and prognosis in patients
with previous coronary artery bypass graft-
ing (from the Post CABG Trial). Am J
Cardiol. 2009;103(3):328-32.
4. Wolanskyj AP, Schwager SM, McClure RF,
Larson DR, Tefferi A. Essential thrombo-
cythemia beyond the first decade: life
expectancy, long-term complication rates,
and prognostic factors. Mayo Clin Proc.
2006;81(2):159-66.
5. Carobbio A, Antonioli E, Guglielmelli P,
Vannucchi AM, Delaini F, Guerini V, et al.
Leukocytosis and risk stratification assess-
ment in essential thrombocythemia. J Clin
Oncol. 2008;26(1)6:2732-6.
6. Barbui T, Carobbio A, Rambaldi A, Finazzi
G. Perspectives on thrombosis in essential
thrombocythemia and polycythemia vera:
is leukocytosis a causative factor? Blood.
2009;114(4):759-63.
7. Kralovics R, Teo SS, Buser AS, Brutsche M,
Tiedt R, Tichelli A, et al. Altered gene
expression in myeloproliferative disorders
correlates with activation of signaling by
the V617F mutation of Jak2. Blood.
2005;106(10):3374-6.
8. Kaptoge S, Di Angelantonio E, Lowe G,
Pepys MB, Thompson SG, Collins R, et al.
C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortal-
ity: an individual participant meta-analysis.
Lancet. 2010;375(9709):132-40.
9. Latini R, Maggioni AP, Peri G, Gonzini L,
Lucci D, Mocarelli P, et al. Prognostic signif-
icance of the long pentraxin PTX3 in acute
myocardial infarction. Circulation.
2004;110(16):2349-54.
10. Salio M, Chimenti S, De Angelis N, Molla F,
Maina V, Nebuloni M, et al.
Cardioprotective function of the long pen-
traxin PTX3 in acute myocardial infarction.
Circulation. 2008;117(8):1055-64.
11. Panteli KE, Hatzimichael EC, Bouranta PK,
Katsaraki A, Seferiadis K, Stebbing J, et al.
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6
and thrombopoietin levels in patients with
chronic myeloproliferative diseases. Br J
Haematol. 2005;130(5):709-15.
12. Vannucchi AM, Pancrazzi A, Bogani C,
Antonioli E, Guglielmelli P. A quantitative
assay for JAK2(V617F) mutation in myelo-
proliferative disorders by ARMS-PCR and
capillary electrophoresis. Leukemia.
2006;20(6):1055-60.
13. Yamasaki K, Kurimura M, Kasai T, Sagara
M, Kodama T, Inoue K. Determination of
physiological plasma pentraxin 3 (PTX3)
levels in healthy populations. Clin Chem
Lab Med. 2009;47(4):471-7.
14. Quist-Paulsen P, Naess IA, Cannegieter SC,
Romundstad PR, Christiansen SC,
Rosendaal FR, et al. Arterial cardiovascular
risk factors and venous thrombosis: results
from a population-based, prospective study
(the HUNT 2). Haematologica. 2010;95(1):
119-25.
15. Boekholdt SM, Kastelein JJ. C-reactive pro-
tein and cardiovascular risk: more fuel to
the fire. Lancet. 2010;375(9709):95-6.
16. Norata GD, Marchesi P, Pulakazhi Venu
VK, Pasqualini F, Anselmo A, Moalli F, et al.
Deficiency of the long pentraxin PTX3 pro-
motes vascular inflammation and athero-
sclerosis. Circulation. 2009;120(8):699-708.
17. Deban L, Russo RC, Sironi M, Moalli F,
Scanziani M, Zambelli V, et al. Regulation
of leukocyte recruitment by the long pen-
traxin PTX3. Nat Immunol. 2010;11(4):328-
34.
18. Ley K. The role of selectins in inflammation
and disease. Trends Mol Med. 2003;9(6):
263-8.
19. Zarbock A, Singbartl K, Ley K. Complete
reversal of acid-induced acute lung injury
by blocking of platelet-neutrophil aggrega-
tion. J Clin Invest. 2006;116(12):3211-9.
